Type 2 Inflammation in Chronic Spontaneous Urticaria: Presentation, Role, and Management.
- 1Allergy Unit, 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, University General Hospital "Attikon", Athens, Greece.
- 21st Department of Dermatology and Venereology, "Andreas Syggros" Hospital for Skin and Venereal Diseases, National and Kapodistrian University of Athens, Athens, Greece.
- 3Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany.
Abstract
Chronic spontaneous urticaria (CSU) is a heterogeneous inflammatory skin disease characterized by recurrent wheals, angioedema, and pruritus, with substantial effects on quality of life. Although mast-cell activation remains the central effector event, increasing evidence implicates type 2 inflammatory pathways in CSU and suggests that the disease shares biological features with established type 2 inflammatory disorders, including atopic dermatitis, asthma, chronic prurigo, and chronic rhinosinusitis with nasal polyps. This review examines the contribution of type 2 inflammation to CSU, its relationship with established autoimmune endotypes, associated biomarkers, and implications for current and emerging therapies. Type 2 cytokines, including IL-4, IL-5, IL-13, and IL-31, together with epithelial alarmins and neuroimmune pathways, interact with IgE-dependent, autoimmune, and other mechanisms to amplify mast-cell activation, inflammation, and pruritus. Importantly, type 2 inflammation should not be regarded as an alternative to the established type I autoallergic/type IIb autoimmune classification, but rather as a partly overlapping and variably expressed inflammatory axis. No validated biomarker currently defines a type 2-high CSU endotype or reliably guides individual treatment selection; total IgE, eosinophils, basophils, autoantibodies, and functional basophil assays provide complementary mechanistic or prognostic information but remain insufficient for precision prescribing. The expanding therapeutic landscape reflects this biological complexity. Omalizumab targets IgE-dependent activation, dupilumab directly inhibits IL-4/IL-13 signaling, whereas BTK inhibitors such as remibrutinib interfere with intracellular mast-cell and basophil signaling across multiple upstream mechanisms. Emerging KIT-directed therapies extend this strategy through direct targeting of the mast-cell compartment. Nevertheless, heterogeneous cytokine signatures and variable therapeutic responses argue against defining CSU as a uniformly type 2-driven disease. Future progress will require prospectively validated biomarker signatures, biomarker-stratified trials, comparative studies of emerging therapies, and long-term evaluation of treatment-free remission and potential disease modification. Defining the contribution and boundaries of type 2 inflammation within the broader pathobiology of CSU may ultimately facilitate the transition from mechanistic understanding to clinically actionable precision medicine in CSU.
Related
- Treatment Choice and Cardiovascular Risk in Chronic Spontaneous Urticaria.
- Lower Serum SCCA2 Detectability in Chronic Spontaneous Compared with Chronic Inducible Urticaria: A Prospective Observational Study
- Efficacy and safety of acupuncture therapy for chronic spontaneous urticaria: a network meta-analysis based on randomized controlled trials
- Comorbidities in Chronic Spontaneous Urticaria: Integrating Disease Drivers and Systemic Consequences
- Evaluation of Fibromyalgia Frequency in Chronic Spontaneous Urticaria Patients Referred to a Tertiary Dermatology Outpatient Clinic.
BibTeX
@article{makris2026type,
title = {{Type 2 Inflammation in Chronic Spontaneous Urticaria: Presentation, Role, and Management.}},
author = {Michael Makris and Niki Papapostolou and Ioannis-Alexios Koumprentziotis and Stamatis Gregoriou},
journal = {Journal of inflammation research},
year = {2026},
month = oct,
doi = {10.2147/jir.s546295},
url = {https://europepmc.org/article/MED/42903800},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Type 2 Inflammation in Chronic Spontaneous Urticaria: Presentation, Role, and Management.
AU - Michael Makris
AU - Niki Papapostolou
AU - Ioannis-Alexios Koumprentziotis
AU - Stamatis Gregoriou
PY - 2026
DA - 2026/10/16
JO - Journal of inflammation research
DO - 10.2147/jir.s546295
UR - https://europepmc.org/article/MED/42903800
AB - Chronic spontaneous urticaria (CSU) is a heterogeneous inflammatory skin disease characterized by recurrent wheals, angioedema, and pruritus, with substantial effects on quality of life. Although mast-cell activation remains the central effector event, increasing evidence implicates type 2 inflammatory pathways in CSU and suggests that the disease shares biological features with established type 2 inflammatory disorders, including atopic dermatitis, asthma, chronic prurigo, and chronic rhinosinusitis with nasal polyps. This review examines the contribution of type 2 inflammation to CSU, its relationship with established autoimmune endotypes, associated biomarkers, and implications for current and emerging therapies. Type 2 cytokines, including IL-4, IL-5, IL-13, and IL-31, together with epithelial alarmins and neuroimmune pathways, interact with IgE-dependent, autoimmune, and other mechanisms to amplify mast-cell activation, inflammation, and pruritus. Importantly, type 2 inflammation should not be regarded as an alternative to the established type I autoallergic/type IIb autoimmune classification, but rather as a partly overlapping and variably expressed inflammatory axis. No validated biomarker currently defines a type 2-high CSU endotype or reliably guides individual treatment selection; total IgE, eosinophils, basophils, autoantibodies, and functional basophil assays provide complementary mechanistic or prognostic information but remain insufficient for precision prescribing. The expanding therapeutic landscape reflects this biological complexity. Omalizumab targets IgE-dependent activation, dupilumab directly inhibits IL-4/IL-13 signaling, whereas BTK inhibitors such as remibrutinib interfere with intracellular mast-cell and basophil signaling across multiple upstream mechanisms. Emerging KIT-directed therapies extend this strategy through direct targeting of the mast-cell compartment. Nevertheless, heterogeneous cytokine signatures and variable therapeutic responses argue against defining CSU as a uniformly type 2-driven disease. Future progress will require prospectively validated biomarker signatures, biomarker-stratified trials, comparative studies of emerging therapies, and long-term evaluation of treatment-free remission and potential disease modification. Defining the contribution and boundaries of type 2 inflammation within the broader pathobiology of CSU may ultimately facilitate the transition from mechanistic understanding to clinically actionable precision medicine in CSU.
SN - 1178-7031
ER -